



**For Immediate Release**

**CONTACT:**  
Matt Flesch  
(847) 282-1154

**Lundbeck Names Staffan Schüberg as President of Lundbeck Inc. U.S. Subsidiary**

DEERFIELD, Ill., Nov. 17, 2010 – H. Lundbeck A/S, headquartered in Denmark, announced today that it has named Staffan Schüberg president of Lundbeck Inc., its U.S. business subsidiary. Mr. Schüberg assumes this new role immediately.

Since joining Lundbeck in 1994, Mr. Schüberg has held a variety of commercial positions and played an integral role in expanding Lundbeck's global business. With success in both sales and marketing, he has led operations at both a country and regional level, in addition to serving as international marketing director of Lundbeck's psychiatry business unit. During this time, he helped launch key company products in both Europe and in the U.S. In 2005, he assumed the position of regional vice president for major markets in Europe, and added the coordination and strategic development of Lundbeck Inc. to his responsibilities last year.

"Staffan has been a key player on the team that has created Lundbeck's global business, driving commercial success both at headquarters in Denmark and at Lundbeck affiliates around the world," said Ulf Wiinberg, chief executive officer of H. Lundbeck A/S. "We have an aggressive and dynamic growth strategy for Lundbeck Inc. in the U.S. and Staffan's proven track record puts us in a great position to achieve our most important goal: applying our special expertise in central nervous system disorders to improve the lives of patients."

The growth strategy for Lundbeck Inc. is driven by its focus on developing and commercializing therapies to address psychiatric and neurological disorders. Lundbeck Inc. recently brought to market a therapy for two difficult-to-treat epilepsies and another to treat a primary symptom of a rare and debilitating neurological disorder. Additionally, Lundbeck has 12 central nervous system (CNS) compounds in development and, by year end, anticipates submitting a New Drug Application (NDA) for a therapy to treat a severe form of childhood epilepsy called Lennox-Gastaut syndrome (LGS) that frequently persists into adulthood.

**About Lundbeck Inc.**

Headquartered in Deerfield, Illinois, Lundbeck Inc., a wholly-owned subsidiary of H. Lundbeck A/S, is committed to providing innovative specialty therapies that fulfill unmet medical needs of people with central nervous system (CNS) disorders and rare diseases for which few, if any, effective treatments are available. For more information, please visit [www.lundbeckinc.com](http://www.lundbeckinc.com).

**About Lundbeck**

H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson's diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 5,900 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with CNS disorders. In 2009, the company's revenue was DKK 13.7 billion (approximately EUR 1.8 billion or USD 2.6 billion). For more information, please visit [www.lundbeck.com](http://www.lundbeck.com).

###